Effect of Ezetimibe on Insulin Secretion in db/db Diabetic Mice

Table 1

Body weight, FBG, FSI, TC, LDL-C, and ISI in different groups at baseline and end of experiment (mean ± SEM).

(a)  

Group	𝑛	Body weight (g)	FBG (mmol/L)	FSI (ug/L)	TC (mmol/L)	LDL-C (mmol/L)	ISI
db/m	Baseline 20	29.10 ± 0.33*	5.51 ± 0.53*	2.43 ± 0.23*	2.65 ± 0.41*	1.65 ± 0.22*	−2.58±0.15
	Terminal 20	35.80 ± 0.54*	5.71 ± 0.63*	2.63 ± 0.31*	2.55 ± 0.53*	1.79 ± 0.27*	−2.69±0.19
db/db	Baseline 20	41.20 ± 3.18	17.30 ± 3.99	8.51 ± 1.26	5.14 ± 0.80	3.88 ± 0.44	−4.95±0.32
	Terminal 20	50.20 ± 4.32	25.9 ± 2.00	9.55 ± 1.20	5.86 ± 0.85	4.91 ± 0.37	−5.49±0.20
Ezetimibe	Baseline 20	40.92 ± 2.84	18.37 ± 4.25	9.01 ± 1.37	5.30 ± 0.77	3.69 ± 0.74	−5.07±0.34
	Terminal 20	45.40 ± 3.81*	18.82 ± 3.99*	7.58 ± 0.67*	4.21 ± 0.63*	2.78 ± 0.62*	−4.38±0.24

Note: db/m: db/m mice without diabetes; db/db: untreated db/db mice with diabetes; ezetimibe: ezetimibe-treated db/db mice with diabetes; *𝑃<0.05 untreated db/db mice versus treated db/db control mice.

(b)  

Group	𝑛	TG (mmol/L)	FFA (mmol/L)	HbA1c (%)
db/m	Baseline 20	1.03 ± 0.22*	2.52 ± 0.39*	5.18 ± 1.21*
	Terminal 20	0.93 ± 0.27*	2.58 ± 0.48*	4.99 ± 1.03*
db/db	Baseline 20	1.99 ± 0.74	3.23 ± 0.87	8.80 ± 2.54
	Terminal 20	2.28 ± 0.49	3.74 ± 0.89	11.46 ± 2.87
Ezetimibe	Baseline 20	2.18 ± 0.45	3.35 ± 0.84	9.08 ± 2.67
	Terminal 20	1.50 ± 0.74*	2.88 ± 0.53*	9.77 ± 2.60*

Note: db/m: db/m mice without diabetes; db/db: untreated db/db mice with diabetes; ezetimibe: ezetimibe-treated db/db mice with diabetes; *𝑃<0.05 untreated db/db mice versus treated db/db control mice.